This morning Amylin Pharmaceuticals Inc.(NASDAQ:AMLN) is declining lower by 24.0 percent as the companies diabetes drug failed to beat a competitors drug in a head to head test. The stock price is nearing its October 2010 low which was $9.50 a share. This double bottom low price will be some short term support for Amylin stock.
Nicholas Santiago
InTheMoneyStocks.com
